Jeffrey Engelman, MD, PhD
Director
Molecular Therapies,
Massachusetts General Hospital Cancer Center

Overcoming Resistance to Targeted Therapies:
Challenges and Opportunities

Dr. Engelman’s research has focused on developing strategies to perturb signal transduction to treat cancers. These studies have focused on receptor tyrosine kinases, the PI3K and MAPK signaling pathways, and the BH3 family members regulating apoptotic responses. In particular, his work has emphasized understanding the basis for sensitivity and resistance to kinase inhibitors in cancers. More recently, his research has explored the variety of mechanisms employed by cancers to become resistant to effective targeted therapies. His work encompasses both laboratory models and clinical specimens. The goal of this research is to unleash the full potential of targeted therapies to improve the lives of patients with cancer.

Dr. Engelman received his Bachelor of Arts in Chemistry from Northwestern University and his MD and PhD degrees from the Albert Einstein College of Medicine. Dr. Engelman completed his medical residency in Internal Medicine at Brigham and Women’s Hospital and a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He joined the Harvard Medical School faculty and Massachusetts General Hospital in 2005. Dr. Engelman was elected a member of the American Society for Clinical Investigation in 2011. Named one of World’s Most Influential Scientific Minds in 2014 by Thomson-Reuters.